Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.46 |
| ▸ | JAK1 | P23458 | 14/20 | 0.46 |
| ▸ | TYK2 | P29597 | 14/20 | 0.46 |
| ▸ | JAK3 | P52333 | 14/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892990 | 0.83 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL7381477 | 0.81 | NPC1 (0.48) | ADRA1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL9102971 | 0.81 | JAK2 (0.43) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL25237331 | 0.79 | JAK2 (0.38) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL8887417 | 0.77 | LMNA (0.47) | ADRA1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL11300658 | 0.76 | EPHB3 (0.55) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL12699179 | 0.74 | JAK2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9923339 | 0.74 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25240695 | 0.74 | JAK2 (0.35) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL25776500 | 0.74 | JAK2 (0.42) | JAK2JAK1TYK2JAK3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155744-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | Lundbeck, H., A/S (DK) | 2010-02-24 | — | — | EP | claimed |
| WO-2008124153-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-10-16 | — | — | WO | claimed |
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4251149-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115301-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. Lindbeck A/S (DK) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | JAK2 4615/4885JAK1 4800/4885TYK2 4594/4885 |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | P2RX7, P2RX3, P2RX2 | JAK2 2312/4885JAK1 4017/4885TYK2 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.